Pulmonary manifestations in antisynthetase syndrome Lung and antisynthetase syndrome

##plugins.themes.academic_pro.article.sidebar##

Published Jul 19, 2018
Download
pdf
Vol. 96 No. 2 (2018): Issue Feb 2018

##plugins.themes.academic_pro.article.main##

Thouraya Ben Salem
Cherifa Abdelkafi
Mounir Lamloum
Imed Ben Ghorbel
Mohamed Habib Houman

Abstract

Introduction:

Pulmonary manifestations are frequent in patients with antisynthetase syndrome which is a particular form of inflammatory myopathies.

Aim:

The aim of this study is to describe clinical features and long term outcome of interstitial lung disease in these patients.

Patients and methods:

This is a retrospective descriptive study in an internal medicine department. Patients with antisynthetase syndrome hospitalized from 2000 to 2014 were collected.

Results:

There were nine patients; five women and four men. The mean age at diagnosis was 54.4 ±11.2 years. Interstitial lung disease was observed in all cases and revealed the disease in five cases. The more frequent aspect in high resolution computer thoracic scan was ground-glass opacities (n=8). Traction bronchiectasis and septal thickening were noted each one, in five cases. Honeycombing was observed in one case. Restrictive syndrome was noted in 4/4 cases. All patients received corticosteroids. Two patients were treated with methotrexate for myositis. Intravenous cyclophosphamide was used in five patients (at diagnosis for severe interstitial lung disease in three cases and after pulmonary function worsening in two other cases). Improvement was noted in seven patients. Two patients died after pulmonary symptom worsening and respiratory insufficiency.

Conclusion:

Interstitial lung disease in patients with antisynthetase syndrome may have a poor prognosis and should be treated at time. Altough the optimal therapy was not clearly established, corticosteroids are considered to be the first line therapy. Immunosuppressive agents as cyclophosphamide, azathioprine or methotrexate may be used in some cases.

Keywords:

Antisynthetase syndrome, Myositis, interstitial lung disease, antinuclear antibodies, immunosuppressive agents, respiratory insufficiency.

##plugins.themes.academic_pro.article.details##

References

  1. Marie I, Josse S, Haltron PY et al. Interstitial lung disease in anti JO1 patients with antisynthetase syndrome. Arthritis care Res 2013;65:800-8
  2. Frikha F, Saidi N, Snoussi M et al. Le syndrome des antisynthétases : à propos de quatre observations et revue de la littérature. Rev Pneumol Clin 2012;68:351-60.
  3. Jouneau S, Hervier B, Jutant EM et al. Les manifestations pulmonaires du syndrome des antisynthétases. Rev Mal Resp 2015;32:618-28.
  4. Bajocchi G, Piro R, Lombardini C, Cavazza A, Facciolongo N. Acute respiratory distess syndrome - an undercover antisynthetase syndrome a case report and review of the literature. Clin Exp Rheumatol 2012;30:424-8.
  5. Ben Ghorbel I, Klii R, Lamloum M et al. Détresse respiratoire aigüe sévère révélant un syndrome des antisynthétases. Rev Med Interne 2009;30(2 Suppl):96.
  6. Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 1996;26:459-67.
  7. Dieval C, Ribeiro E, Mercié P, Blanco P, Long-Boursier M. Antisynthetase syndrome : a retrospective study of 14 patients. Rev Med Interne 2012;33:76-9.
  8. Hervier B, Devilliers H, Stanciu R et al. Hierarchical cluster and survival analysis of antisynthetase syndrome: phenotype and outcome are correlated wiyh anti-t RNA synthetase antibody specificity. Autoimmun Rev 2012;12:210-7.
  9. Marie I, Josse S, Decaux O et al. Comparison of long-term out between anti JO1 and anti PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev 2012;11:739-45.
  10. Labirua-Iturburu A, Selva-O'Callaghan A, Martinez-Gomez X, Trallero-Araguas E, Labrador-Horrillo M, Vilardell-Tarrès M. Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease. Clin Exp Rhumatol 2013;31:436-9.
  11. Cavagna L, Caporali R, Abdi-Ali L, Dore R, Meloni F, Montecucco C. Cyclosporine in anti-Jo1 patients with corticoseroid-refractory interstitial lung disease. J Rheumatol 2013;40:484-92.
  12. Basnayake C, Cash K, Blumbergs P, Limaye V. Use of rituximab in histologically confirmed idiopathic inflammatory myositis: a case series. Clin Rheumatol 2015;34:371-7.
  13. Nalotto L, Iaccarino L, Zen M et al. Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature. Immunol Res 2013;56:362-370.